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Background: There is still debate regarding the use of surgery in the management of non-small 
cell lung cancer patients with N2 disease. The primary aim of the present study was analysis of the 
results of initial operations in non-small cell lung cancer patients with single-level N2 disease. 
Methods: Ninety-four patients with the disease who underwent initial surgery consisting of 
complete resection of the primary site plus systematic lymphadenectomy were examined. We also 
immunohistochemically examined lymphatic vessel density (LVD) and vascular endothelial growth 
factor (VEGF)-C expression. 
Results: The overall 5- and 10-year survival rates for the 94 patients were 27.1% and 12.1%, 
respectively, with a median survival of 22 months. When stratified by skipping status, the 5-year 
survival rates for the patients in skip-N2 and non-skip-N2 groups were 33.4% and 19.8%, 
respectively (p=0.0189). Skip metastasis, T factor, subcarinal lymph node metastasis, and adjuvant 
chemotherapy were recognized as independent prognostic indicators. In both skip- and non-skip-N2 
groups, distant relapse was the dominant pattern of recurrence. While the peritumoral LVD was 
associated with VEGF-C expression in tumors, lymphangiogenic profile appeared to be different 
between skip-N2 and non-skip-N2 tumors, suggesting different nodal metastatic process.  
  Conclusions: Lung cancer patients with single-level N2 disease are a oncologically 
heterogeneous cohort. Although further studies involving randomized comparisons are required, the 
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poor outcomes found here indicate that the initial operation has yet to be validated for 
patients with this disease.  
 
Introduction 
Nodal involvement is crucial for the oncological outcome in patients with non-small cell lung 
cancer. Induction chemo- or chemoradiotherapy followed by salvage surgery are well-accepted 
forms of treatment for patients with ordinal N2 disease. On the other hand, recent clinical trials have 
begun to demonstrate absolute survival benefit of postoperative adjuvant chemotherapy in selected 
cases of non-small cell lung cancer patients, and recent guidelines generally recommend adjuvant 
chemotherapy for patients with completely resected stage IB-III non-small cell lung cancer. In this 
situation, in contrast to alternate induction treatment followed by surgery, the use of an initial 
operation plus postoperative adjuvant chemotherapy in the management of patients with resectable 
single-level N2 disease has become a matter of debate. Although studies of the molecular events 
underlying nodal metastasis in lung cancer are not yet conclusive, some investigators have also 
postulated a subgroup of skip N2 disease with more favorable therapeutic results as compared to 
those with non-skip N2 disease [1-7]. In the present study, we reviewed our experience with 
non-small cell lung cancer patients with single-level N2 disease who underwent initial operation and 
performed a retrospective analysis of the surgical results. As a possible nodal metastatic process, we 
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further explored the lymphangiogenic profile in this unique subgroup of N2 disease.   
 
Materials and Methods 
Patients  
Among 1,751 primary non-small cell lung cancer patients who underwent operations at Kanazawa 
University Hospital between 1981 January and 2004 May, 325 patients were diagnosed as having 
mediastinal nodal involvement after resection of the primary site with systematic nodal dissection of 
both the hilar and mediastinal lymph nodes. Of those with N2 disease, 94 patients (52 men and 42 
women) with a median age of 67 years (range, 36-82 years) had single-level N2 disease. All of these 
94 patients underwent initial operation consisting of complete resection of the primary site plus 
systemic lymphadenectomy. Until around 2001, clinical assessment of nodal metastasis was 
performed according to CT findings and 201Tl scan results. From about 2001, FDG-PET has been 
routinely performed in place of 201Tl scan as a less invasive diagnostic tool. Lymph node biopsy 
through mediastinoscopy was not performed routinely and was performed selectively in patients 
with clinical N2 diagnosis based on the CT findings and 201Tl/PET scan results. Thirty-three of 94 
patients were diagnosed as having clinically single-level N2 disease by mediastinoscopy. For 
patients with clinical single-level N2 disease, we elected to perform initial operation. All patients 
gave written informed consent before surgery. Operative procedures included lobectomy in 77 cases 
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(chest wall resections were combined in 4 cases, bronchoplastic procedures were used in 3 cases, 
circumferential aortic resection was combined in one case), bilobectomy in 9 cases, pneumonectomy 
in 6 cases, and segmentectomy in 2 cases. The pathological types were as follows: 52 cases with 
adenocarcinoma, 37 cases with squamous cell carcinoma, 3 cases with large cell carcinoma, and 2 
cases with adenosquamous carcinoma. The pathological stages according to the TNM classification 
[8] were, 86 cases in stage IIIA and 8 cases in stage IIIB. The mediastinal lymph nodes were 
identified and numbered (level 1-9) by the lymph node map [9]. Fifty of these 94 patients were free 
from metastasis in the hilar and intrapulmonary lymph nodes as determined by histopathological 
examination (skip-N2) and the others showed combined hilar or intrapulmonary nodal metastasis 
(non-skip N2). The basic clinical features of the patients are summarized in Table 1.  
 
Immunohistochemistry and assessment of lymphatic vessel density (LVD)  
  The primary antibodies used in the study were an anti-vascular endothelial growth factor 
(VEGF)-C polyclonal antibody (Santa Cruz Biothechnology, Inc, Santa Cruz, CA, USA) diluted 
200-fold and D2-40 monoclonal antibody (Nichirei Corporation, Tokyo, Japan) diluted 100-fold. 
After reviewing the hematoxylin and eosin-stained slides of the tumor specimens, we selected blocks 
of the invasive edge in the tumor area. Paraffin-embedded tumor tissues were sectioned into a 4-μm 
thickness and were deparaffinized and immunohistochemical staining was performed using the 
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labeled streptavidin-biotin method, as described previously [10.11].  
 The lymphatic vessel densities were assessed in both intratumoral and peritumoral (within and 500 
μm outside the tumor border) lesions. The areas of highest lymphatic vascularization were chosen 
under low power (100x magnification), 3 areas with the highest LVD were identified. The lymphatic 
vessel count was performed with a computer-aided image processing application (Win ROOF, 
Mitani Corp., Fukui, Japan). Lymphatic vessel counts from 3 areas were averaged and LVD was 
defined. VEGF-C staining was considered positive when more than 10% of the tumor area was 
stained.   
 
Statistics   
  The association between variables was analyzed with the χ2 test. The Mann-Whitney U test for 
differences in mean values was used for comparison of nominal data. To assess the prognostic effects 
on overall survival, age, tumor size, and LVD were classified as high or low relative to the median 
value. Survival curves were obtained by the Kaplan-Meier method and compared univariately by the 
log-rank test. Zero time was the date of surgical treatment. Skip metastasis, age (≥67 vs. <67 years), 
sex, T factor (T1,2 vs. T3,4), pathological type, location of the primary tumor (right vs. left, upper 
lobe vs. lower lobe), tumor size (≥3.5 vs. <3.5 cm), clinical N2, adjuvant treatment, location of 
metastatic mediastinal lymph node (subcarinal lymph node metastasis, upper mediastinum vs. lower 
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mediastinum), and LVD were included in the univariate assessment of prognostic indicators. 
Clinicopathological and biological factors found to have a P value of less than 0.20 in the univariate 
analysis were entered into stepwise multiple logistic regression analysis for the determination of 
statistically significant, independent prognostic factors. Mean values are shown ± the standard error. 
 
Results 
The Upper lobe was more frequently the primary site in the skip-N2 group as compared with the 
non-skip-N2 group (p=0.0041). There were no significant differences in gender, age, tumor size, 
location of the primary site (right vs. left), histological type, percentage of patients with 
postoperative adjuvant therapy (systemic chemotherapy with/without radiation therapy), 
pathological stage (IIIA vs. IIIB), or the number of patients with clinical N2 disease between the two 
groups (Table 1).  
With respect to the mediastinal spread of metastasis, if the primary tumor was located in an upper 
lobe, nodal metastasis was mainly detected in the upper mediastinal area (54/57 patients). In patients 
with the primary tumor in the left lower lobe, nodal involvement was detected predominantly in the 
lower mediastinal area in non-skip-N2 group (11/11 patients). However, the dominant area affected 
was the upper mediastinal area (paraaortic or subaortic) in the skip-Ns group (3/5 patients). In 
patients with the primary site in the right lower lobe, although metastases were detected mainly in 
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the lower mediastinal area (16/20 patients), the upper mediastinal area was also affected in the 
non-skip-N2 group (4/12 patients)(Figure 1).  
In total, the overall 5-year and 10-year survival rates for the 94 patients with single-level N2 
disease who underwent complete resection were 27.1% and 12.1%, respectively, with a median 
survival of 22 months (Figure 2). The effects of skip metastasis on survival were evaluated, and the 
median survival periods in skip-N2 and non-skip-N2 groups were 31 months and 20 months, 
respectively. The 5-year survival rates were 33.4% and 19.8%, respectively. The difference was 
statistically significant (p=0.0189)(Figure 3). Univariate analysis indicated that male gender 
(p=0.020), non-skip single-level metastasis (p=0.015), pathological type other than adenocarcinoma 
(p=0.007), T3,4 factor (p=0.0003), clinical N2 (p=0.033), the presence of subcarinal lymph node 
metastasis (p=0.043), and no postoperative adjuvant chemotherapy (p=0.048) were significantly 
associated with a poorer outcome. Stratified by skip and non-skip metastasis, the components were 
different between skip-N2 and non-skip-N2 group, with the exception of T factor (Table 2). As a 
result of multivariate analysis, non-skip metastasis, T3,4 factor, subcarinal lymph node metastasis, 
and no postoperative adjuvant chemotherapy were independent negative prognostic indicators. 
Stratified by skip and non-skip metastasis, peritumoral LVD showed independent negative 
prognostic impact on overall survival in non-skip-N2 group (Table 3). 
Among the patients who died of lung cancer, the pattern of recurrence could be identified in 46 
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patients. In the skip-N2 group, among 19 patients whose recurrent pattern could be identified, 13 had 
developed distant metastases, 3 had relapsed due to local recurrence, and 3 had developed both 
patterns of recurrence at the time of diagnosis. In the non-skip-N2 group, among 27 patients with 
identified recurrent pattern, 17 had developed distant metastases, 4 had relapsed due to local 
recurrence, and 6 had developed both patterns at the time of diagnosis. Clearly, distant relapse was 
the dominant pattern of recurrence in both groups. 
In comparison with the consecutive H&E-stained sections, staining for D2-40 was detected 
predominantly in lymphatic vessels both within the tumor and in the peritumoral area (Figure 4). No 
immunostaining was identified in the tumor cells or blood vessls, as described previously. The mean 
LVD within tumor area in the skip-N2 group tended to be greater than that in the non-skip-N2 group 
[72.8±4.5 (range 23-194) vs. 63.2±4.5 (range 15-171), p=0.074]. The mean LVD within the 
peritumor area in skip-N2 and non-skip-N2 groups were 64.4±4.1 (range 12-141) and 53.0±3.0 
(range 17-100), respectively. The difference was statistically significant (p=0.037). The impact of 
LVD as a prognostic indicator was not statistically significant in the total patient group. However, in 
skip-N2 patients, LVD in the peritumoral area appeared to have a weaker relationship with outcome, 
although the value only trended toward significance.  
VEGF-C antigens were mainly identified in the cytoplasm of tumor cells (Figure 5). The 
percentage of positive tumors were 56.0% (28/50) in skip-N2 group and only 29.6% (12/44) in 
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non-skip-N2 group (p=0.0126). The relationship between VEGF-C expression and LVD was 
summarized in Table 4. Peritumoral LVD and VEGF-C expression were strongly associated 
(p=0.0035) in skip-N2 group, but not in non-skip-N2 group. No association was found between 
intratumoral LVD and VEGF-C expression. 
 
Discussion 
In the present study, a relatively regular distribution of the spread of mediastinal nodal metastasis 
was found in both skip and non-skip groups. That is, if the primary tumor was located in the upper 
lobe, nodal metastasis was detected mainly in the upper mediastinal area, while in patients with the 
primary tumor in the left lower lobe, nodal involvement was detected frequently in the lower 
mediastinal area. However, 7 patients (19.4% of the patients in whom the primary site was located in 
the lower lobe) had isolated nodal spread in the upper mediastinal area from the lower lobe and 3 
patients (5% of those in whom the primary site was in the upper lobe) had nodal metastasis in the 
lower mediastinal area from the upper lobe. The lymphatic channel draining directly into the 
mediastinal area has been proposed as a possible metastatic route of skip mediastinal spread. Based 
on an autopsy study, Riquet and his colleagues demonstrated incidences of direct passage into the 
mediastinal nodes of 22.2% and 25% on the right and left sides, respectively. Interestingly, they also 
reported that direct passage was observed more frequently in the segments of the upper lobes [12]. 
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The observation in the present study that the upper lobe was the predominant site of primary lung 
cancer with mediastinal skip nodal metastasis may represent the anatomical distribution of these 
direct passages as suggested by Riquet [7]. This relationship between the location of the primary site 
and the frequency of mediastinal skip nodal metastasis was also documented by other 
investigations[3,7,13,14]. From the viewpoint of sentinel lymph node mapping, the results of 
recently launched clinical trials support the anatomical concept. While the percentage of skip 
metastasis in lung cancer patients with N2 disease has been reported to be around 20-40% [1-7], 
sentinel node mapping in non-small cell lung cancer patients in various stages revealed a similar 
percentage of mediastinal (N2) sentinel nodes of 16.7-31% with a high sensitivity rate of more than 
90% [16-18]. Arguably, the direct drainage system appears the most plausible main channel of skip 
mediastinal nodal spread of cancer cells.  
The concept that N2 nodes with a direct drainage system should be included in N1 is of interest as 
an answer to the questions regarding the relatively preferable surgical results in the skip-N2 group. 
However, some peculiar clinical features cannot be explained only by the anatomical and mechanical 
drainage system. As the results of immnunohistochemical staining of N1 lymph nodes with 
anti-cytokeratin antibodies, one previous report indicated that microscopic spread of cancer cells 
could be detected in 17.6% of patients with skip-N2 disease [4]. Using immunohistochemical 
staining for cytokeratin in 3,081 lymph node samples obtained from 181 non-small cell lung cancer 
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patients diagnosed as being in stage I by conventional histopathological examination, we previously 
found nodal micrometastasis in 44 patients [19]. Twenty-six of these patients had micometastases in 
a single level of the mediastinal area. Of these 26 patients, 19 had a skip pattern and 7 showed a 
non-skip pattern with involvement of N1 micrometastases (data not shown). Here, if the small 
amount of cancer cells detected in N1 lymph nodes were the trace or footprint of cancer 
dissemination, some cancer cells may pass through the sentinel node and grow in other regional 
nodes. This possibility warrants further study and the possible dual lymphatic pathways with 
coexisting N1(-)N2 and N1(+)N2 remains to be defined [7]. 
As most of skip metastases are restricted to a single region, the disease is likely to be localized. 
However, 5-year survival rates of patients with skip N2 disease have been reported to be 21-51% 
even after complete resection [1-7]. In our series, the 5-year survival rate of the patients with 
skip-N2 disease was 33.4% despite complete resection with systematic lymphadenectomy Consistent 
with previous reports [1-7], survival of patients with non-skip-N2 disease was worse than that of 
patients with skip-N2 disease. The present study also showed that distant metastasis is the dominant 
pattern of recurrence. In comparison with patients with nodal micrometastasis, the 5-year survival 
rate of the 26 patients with single-level mediastinal nodal micrometastasis was 57.7% despite 
systematic lymph node dissection, although survival was significantly better than the 94 patients 
with single-level metastasis presented here (p=0.0033)(data not shown). Besides T factor, among the 
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various clinicopathological factors, while histological type and adjuvant therapy showed significance 
in the skip-N2 group, tumor size and clinical N2 status showed statistical significance in the 
non-skip-N2 group. These observations suggested that it is necessary to consider non-small cell lung 
cancer patients with single station N2 disease as an oncologically heterogeneous subgroup with 
different biological behavior, and a number of patients in this group have a risk of systemic disease 
even if the nodal metastasis is the skip pattern. 
  Newly formed tumor vessels have been shown to have structural and functional abnormalities 
such as loss of vascular hierarchy, arterio-venous shunting. Larger numbers and greater surface area 
of immature neo-vessels are thought to be a driving force of cancer metastasis via blood or 
lymphatic routes. It is interesting to note that, among the members of the vascular endothelial growth 
factor (VEGF) family, VEGF-C/D and VEGF receptor (VEGFR)-2/3 pathways are involved in 
induction of “lymphangiogenesis” and these specific pathways involved in lymphangiogenesis have 
been shown to be different from those in hemangiogenesis [20]. Of more direct clinical relevance, 
recent reports further indicated that lymphangiogenesis is an indicator of lymph node metastasis in 
various malignant solid tumors such as cutaneous melanoma, head and neck squamous cell 
carcinoma, malignant pleural mesothelioma, by direct counting of lymphatics [21-23]. The findings 
in of basic research have suggested that peritumoral functional lymphatics are important for 
lymphatic metastasis [24]. In lung cancer, although the association of lymphangiogenesis with nodal 
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metastasis is still an open question, previous research conducted in our laboratory confirmed a 
significant association between tumor-induced VEGF–C and VEGFR-3 expression in vascular 
endotheluial cells and lymphatic vessel invasion and lymph node metastasis in non-small cell lung 
cancer [25]. We have also confirmed a positive association between tumor-induced VEGF-C and 
nodal micrometastasis, the earliest phase of cancer nodal spread, in non-small cell lung cancer [11]. 
In the present study, for direct assessment of lymphatic vessels using paraffin-embedded tumor 
tissue specimens, we used a monoclonal antibody D2-40, which was originally introduced as an 
antibody against testicular oncofetal and testicular germ cell tumors antigens. It has already been 
shown to be a specific marker of tumor-associated lymphatic endothelium with no cross-reactivity 
with blood vessel endothelium [26-29]. To our knowledge, this is the first time this antibody has 
been applied to non-small cell lung cancer specimens to assess LVD. Consistent with the 
observations of previous studies, lymphatic vessels were clearly detected both within the tumor and 
in the peritumoral area in lung cancer tissue. Interestingly, in the assessment of LVD in the peritumor 
area, we found a significant difference in LVD and VEGF-C expression between the skip-N2 and 
non-skip-N2 groups. The results demonstrated here suggested that the dependency of nodal 
metastasis on lymphangiogenesis is different between skip and non-skip nodal metastasis. Although 
the LVD assessed is unrelated to outcome in the total patient population, survival of patients with 
high LVD tended to be worse than that of patients with low LVD in the skip-N2 group. The 
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interrelation between LVD and outcome was similar to that between blood vessel density and 
outcome. Recent studies have postulated different angiogenic profiles, i.e., angiogenic and 
non-angiogenic, in non-small cell lung cancer [30-32]. In non-angiogenic tumors, cancer cell nests 
fill the alveolar space without destruction of parenchyma, co-opting the septal blood vessels[30]. 
Some investigators suggested that non-angiogenic profile was associated with negative prognostic 
indicators and angiogenesis-related parameters, such as tumor vascular density, can only be of 
prognostic value in tumors with angiogenic profile [32]. Similarly, skip-N2 and non-skip-N2 tumors 
may have different lymphangiogenic profiles, resulting in different LVD and corresponding different 
outcomes.  
  In conclusion, non-small cell lung cancer patients with single-level N2 are included in 
the heterogeneous cohort of patients. Although the survival of patients with skip-N2 
was superior to that of patients with non-skip-N2, surgical results after the initial 
operation were not satisfactory. Therefore, for patients with single-level N2, the same 
tactic as used for patients with ordinal N2 is warranted. While the 
anatomical/mechanical lymphatic drainage systems appear to pertain to the formation 
of isolated skip mediastinal nodal metastases, our results further suggested differences 
in metastatic process with different lymphangiogenic profiles between skip and 
non-skip single-level N2 patients. Further studies are required to characterize the 
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potential causal relationship between lymphangiogenesis and lymphatic metastasis in 
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Fig. 1. Intramediastinal spread of metastasis related to the primary tumor sites. RUL, 
right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left 
upper lobe; LLL, left lower lobe. Open circles, skip metastasis; closed circles, 
non-skip metastasis. 
Fig. 2. Kaplan-Meier survival plots for 94 NSCLC patients with single-level N2 disease. 
      The survival curve is combined with lines represent the 90% confidence 
interval. 
Fig. 3. Kaplan-Meier survival plots for 94 NSCLC patients with single-level N2 disease 
subdivided according to skip (n=50) or non-skip (n=44) status. The difference in 
survival between the two groups was significant (p=0.015). The survival curves 
are combined with lines represent the 90% confidence interval. 
Fig. 4. Immunohistochemical staining for D2-40 (A). In comparison with consecutive 
H&E-stained section (B), D2-40 staining was detected predominantly in 
lymphatic vessels. No immunostaining was identified in the tumor cells or blood 
vessels. 
Fig. 5. Immunohistochemical staining for VEGF-C. VEGF-C antigens were mainly 
identified in the cytoplasm of tumor cells.  
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Table 1. Basic Clinical and Pathological Characteristics of The 94 Lung Cancer Patients With Single-level N2  
 
Variable   Total  Skip   Non-skip  
Patients (n)  94  50  44  
Sex (n)                                                                         
  Male   52  29  23  
  Female   42  21  21 
Mean age (y)  65.5±9.5  66.5±8.1  64.4±10.9 
Mean tumor size (cm) 4.0±2.0  4.0±1.8  4.0±2.3  
Location-1 (n)        
  Right   48  28  20  
  Left   46  22  24 
Location-2 (n)        
  Upper lobe  57  36  21  
  Middle lobe   1   1   0 
  Lower lobe  36  13  23 
Histological types (n)            
  Adenocarcinoma  52  27  25  
  Squamous cell   37  20  17 
carcinoma 
  Others    5   3   2 
T factor (n)        
  T1   25  16   9 
  T2   49  25  24 
  T3   12   6   6 
  T4    8   3   5 
Pathological stage (n)        
  IIIA   86  47  39 
  IIIB    8   3   5 
Clinical N factor (n) 
N0   54  32  22  
N1    7   2   5 
N2   33  16  17 




Table 2. Univariate Analysis of Prognostic Factors 
Factors        Total        Skip        Non-skip 
P value  Hazard ratio P value  Hazard ratio P value  Hazard ratio 
   (95% CI)   (95% CI)   (95% CI) 
Skip metastasis 0.015  0.3537 
      (1.059-1.733)  
Age  0.331  0.889   0.355  0.852  0.363  0.853 
        (0.701-1.128)        (0.602-1.195)        (0.608-1.207) 
Sex  0.020  1.328   0.122  1.309  0.102  1.326 
(1.045-1.702)        (0.930-1.878)        (0.944-1.888) 
Histological type 0.007  1.382   0.013  1.535  0.153  0.784 
 (adeno vs others)       (1.090-1.756)        (1.092-2.187)        (0.560-1.096) 
T factor  0.0003  3.019  0.001  2.964  0.014  2.683 
 (T1,2 vs T3,4)       (1.703-5.161)        (1.092-2.187)        (1.234-5.521) 
Tumor size 0.005  1.409   0.087  0.741  0.044  1.432 
(1.105-1.811)        (0.517-1.043)        (1.009-2.048) 
Clinical N2 0.033  1.301   0.345  1.184  0.035  1.444 
(1.020-1.653)        (0.827-1.671)        (1.026-2.034) 
Subcarinal (#7) 0.043  1.928   0.105  0.446  0.132  0.516 
LN metastasis        (1.022-3.410)        (0.193-1.209)        (0.237-1.242) 
Adjuvant therapy 0.048  1.319   0.039  1.507  0.681  0.921 
(1.001-1.714)        (1.019-2.196)        (0.638-1.391) 
Location-1 0.730  0.958   0.723  1.063  0.632  1.086 
 (right vs left)       (0.752-1.216)        (0.756-1.515)        (0.773-1.533) 
Location-2 0.098  0.814   0.233  0.792  0.867  0.971 
 (upper vs lower)       (0.641-1.040)        (0.554-1.174)        (0.690-1.358) 
Location of LN 0.125  0.825   0.296  0.811  0.619  0.919 
 Metastasis       (0.650-1.056)        (0.572-1.186)        (0.657-1.287) 
(upper med. vs 
lower med.) 
*`LVD (1)  0.577  0.872  0.829  0.927  0.557  0.816 
(within tumor)       (0.536-1.410)           (0.463-1.839)        (0.409-1.612) 
LVD (2)  0.220  0.756  0.166  0.593  0.184  0.604 
(peritumor)       (0.457-1.239)         (0.265-1.234)        (0.293-1.280) 
*LVD, lymphatic vessel density 
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Table 3. Multivariate Analysis of Prognostic Factors 
 
Factors        Total        Skip        Non-skip 
P value  Hazard ratio P value  Hazard ratio P value  Hazard ratio 
   (95% CI)   (95% CI)   (95% CI) 
Skip metastasis 0.032  1.311 
       (1.022-1.686) 
T factor  <0.001  3.873  0.025  2.923  0.004  3.913 
(T1,2 vs T3,4)      (2.127-6.866)       (1.153-6.862)       (1.572-9.358) 
Subcarinal (#7) 0.001  3.10  0.025  3.318  0.004  4.606 
LN metastasis      (1.578-5.799)       (1.176-8.197)       (1.555-12.347) 
Adjuvant therapy 0.011  1.439  0.060  1.475 
       (1.087-1.880)       (0.982-2.191) 
*LVD (peritumor)       0.021  2.644 
             (1.159-6.042) 





Table 4. Lympatic Vessel Density (LVD) and VEGF-C Expression in Tumors 
 











































*LVD, lymphatic vessel density 
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